TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01303029
Drug: Gemcitabine+erlotinib+capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Capecitabine will be administered orally 1.660 mg/m2 day from day 1 to day 21. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
Study: NCT02555852
Drug: roxatidine
Normalized name: ROXATIDINE
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a ≥ 30 day NSAID prescription.
Study: NCT02555852
Drug: lafutidine
Normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a ≥ 30 day NSAID prescription.
Study: NCT01489891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applying of 5 puff controlled released (50 mg) transoral spray of placebo (excipients of trade mark of lidocaine ensuring the patient masking).
Study: NCT00574613
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream 0,3 ml once a day (3 months)
Study: NCT02832778
Drug: Rifinah or local generics
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if \<50kg.)
Study: NCT03364491
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 cc normal saline administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
Study: NCT00281944
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00281944
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00615433
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebor Comparator
Study: NCT03780075
Drug: 1.11GBq of 177Lu-EB-PSMA-617
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were intravenous injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
Study: NCT03780075
Drug: 2.00 GBq of 177Lu-EB-PSMA-617
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were intravenous injected with the dose about 2.00 GBq (54 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
Study: NCT03780075
Drug: 3.70GBq of 177Lu-EB-PSMA-617
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were intravenous injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
Study: NCT01605916
Drug: AZD6244
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet Oral bid
Study: NCT00185367
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-2: 3.0 mg EV; Day 3-7: 2.0 mg EV + 2.0 mg DNG; Day 8-24: 2.0 mg EV + 3.0 mg DNG; Day 25-26: 1.0 mg EV; Day 27-28: placebo;In addition SH D 593 B (Miranova) matching placebo
Study: NCT02374684
Drug: Methosulide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolerability Study:~Period I:Single oral administration,dose-escalation of Methosulide(six dose groups:25mg-250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg ,group 2:depending on the adverse drug reaction,150mg/250mg)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Methosulide(three dose groups:50mg,100mg,200mg/250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg~,group 2:depending on the adverse drug reaction,150mg/250mg)~Food Effect on the Pharmacokinetics:~single dose(100mg),two status(Feeding and fasting), washout period(7 days)
Study: NCT02374684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match with experimental groups
Study: NCT04493502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT04493502
Drug: LY3041658
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01771107
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02407392
Drug: Acetic Acid
Normalized name: Acetic acid
DrugBank: Acetic acid (DB03166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During endoscopy Acetic acid will be sprayed onto Barrett's oesophagus and targeted biopsies of taken.
Study: NCT00000473
Drug: fatty acids, omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02108990
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00255567
Drug: Paromomycin sulphate
Normalized name: Paromomycin sulphate
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin sulphate
Study: NCT00255567
Drug: SSG and Paromomycin sulphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSG and Paromomycin Sulphate 17 days
Study: NCT02507219
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.
Study: NCT01021215
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg twice daily given orally for 6 days
Study: NCT02691533
Drug: ω3 PUFA (Polyunsaturated fatty acids) (10% Omegavan 100 ml)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02691533
Drug: ω6 PUFA (Polyunsaturated fatty acids) (10% Intralipid 100 ml)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02691533
Drug: No Lipid Emulsion/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04039477
Drug: KZR-616
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 1 week then 45 mg for 12 weeks
Study: NCT02592408
Drug: 14DPQ on Day 42
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 day primaquine starting on day 42
Study: NCT02433340
Drug: ABT-122
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01920854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01797796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
Study: NCT00591357
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
Study: NCT00530179
Drug: R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 - 21 DAY Cycles of R-CHOP
Study: NCT03745261
Drug: YCC capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Yong Chong Cao (YCC)capsule (Kecai®, Guangdong daguang pharmaceutical group Co., Ltd), 1 g each time, three times a day.
Study: NCT03732404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive plain water with the same volume and timing of treatment.
Study: NCT04360343
Drug: Film-coated tablet
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: uncoated tablet
Study: NCT01052129
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen Sodium Tablets 550 mg
Study: NCT00335439
Drug: ketorolac tromethamine 0.5% (Acular®)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00979810
Drug: 18F-FLT PET Scan
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will undergo MRI and 18F-FLT PET scans of the brain. A IV catheter will be placed in a superficial hand or arm vein for administration of 18F-FLT (approximately 370 MBq), prepared by the MSKCC Radiochemistry Core Facility. A second venous catheter will be placed in the opposite hand or arm for venous blood sampling. If a central venous catheter is present, it will be used for blood sampling or radiopharmaceutical administration, and only a single venous catheter will be placed. Sequential blood samples may be obtained following 18F-FLT infusion for assaying whole blood and plasma radioactivity. All catheters will be removed at the end of the day.
Study: NCT02218021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02096315
Drug: POL7080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT00662233
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00662233
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00701532
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: duration 90 days
Study: NCT00313872
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI regimen D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan
Study: NCT01321151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is a sugar pill. The route of administration is oral, once-a-day for 30 days after injury.
Study: NCT00366262
Drug: PLA-695
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00366262
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00366262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02274974
Drug: lidocaine and Epinephrine
Normalized name: epinephrine / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The wound of C.S will be infiltrated before closure of the skin, with 20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000.
Study: NCT00758407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage according to an individual titration schedule
Study: NCT02266329
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules of placebo identical in appearance to prazosin capsules titrated in the same manner as prazosin.
Study: NCT02346487
Drug: LPV/RTV pellets and AZT/3TC or ABC/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:~* Between 3 and 5.9kg: 2 capsules twice a day~* Between 6 and 9.9kg: 3 capsules twice a day~* Between 10 and 13.9kg: 4 capsules twice a day~* Between 14 and 19.9kg: 5 capsules twice a day~* Between 20 and 24.9kg: 6 capsules twice a day~Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:~* Between 3 and 5.9kg: 1 tablet twice a day~* Between 6 and 9.9kg: 1.5 tablets twice a day~* Between 10 and 13.9kg: 2 tablets twice a day~* Between 14 and 19.9kg: 2.5 tablets twice a day~* Between 20 and 24.9kg: 3 tablets twice a day
Study: NCT03751059
Drug: Bromfenac 0.07% Oph Susp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac 0.07% Oph Susp to be used post-operatively (week 1 to month 3) by one treatment group.
Study: NCT02845843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
Study: NCT01667120
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac 0.5mg/kg IV q8h x 72h.
Study: NCT01667120
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline 1ml/kg
Study: NCT00383877
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05028907
Drug: 5 mg chloramphenicol, 1 mg dexamethasone sodium phosphate, 0.25 mg tetryzoline hydrochloride, 2 mg Hydroxypropyl Methyl Cellulose, 10 mg α-tocopherol acetate and 8 mg macrogol 400).
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
Study: NCT05028907
Drug: sodium hyaluronate, polyethylene and propylene glycol based) three times daily for three months
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
Study: NCT02465853
Drug: Physiological saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection 0.9% Physiological saline solution\<1.0 ml
Study: NCT01394991
Drug: Epoetin alfa 450 IU/kg once a week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 IU/kg once a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
Study: NCT04682444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients ingested placebo tablets after meal without chewing in the dose 0.5 g (2 tablets), 3 times a day, for 7 days.
Study: NCT01394991
Drug: Epoetin alfa 150 IU/kg 3 times a week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU/kg 3 times a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
Study: NCT01466361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01394991
Drug: Epoetin alfa 450 IU/kg once a week (QW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
Study: NCT01394991
Drug: Epoetin alfa 150 IU/kg 3 times a week (TIW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
Study: NCT03361280
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers are administered as described in arms.
Study: NCT00417261
Drug: AXT914
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02275832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00934375
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02414282
Drug: F 18 T807
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study: NCT00995969
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g (w/w) placebo cream applied to both target lesions twice daily
Study: NCT01813929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.
Study: NCT01851993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline
Study: NCT04670601
Drug: Flurbiprofen Test 8.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
Study: NCT04670601
Drug: Flurbiprofen Reference 8.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
Study: NCT02283788
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02479529
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration and weaning of norepinephrine is based on dynamic arterial elastance
Study: NCT02479529
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure, cardiac output), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
Study: NCT02230579
Drug: MMV390048 80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied as powder in bottle formulation for reconstitution pre-dose
Study: NCT02230579
Drug: MMV390048 120mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied as powder in bottle formulation for reconstitution pre-dose
Study: NCT02283788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04482686
Drug: Doxycycline Hcl
Normalized name: doxycycline HCl
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 day treatment
Study: NCT03592901
Drug: brachial plexus anesthesia
Normalized name: ACCU-BLOC PLEXUFIX BRACHIAL PLEXUS ANESTHESIA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia to some part of the brachial plexus prior to surgery. Patients are already receiving this regardless of participation in study.
Study: NCT02245737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00905372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenously (IV) every 4 weeks for 80 weeks
Study: NCT03540979
Drug: Endometrin 100Mg Vaginal Insert
Normalized name: Endometrin 100mg Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal tab for lutheal support
Study: NCT03756987
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be injected in the erector spinae plane.
Study: NCT04279392
Drug: Zoledronic Acid 5 mg/Bag 100 ml Inj
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronic acid infusion
Study: NCT04279392
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion
Study: NCT00355459
Drug: Tetracycline: Doxycycline analog
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00217308
Drug: Lactobacilli GR-1 and RC-14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Lactobacilli will be compared to placebo
Study: NCT00821574
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvastatin: daily 80 mg, oral
Study: NCT02703051
Drug: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03735810
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT01238783
Drug: AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular dosed 3 times per day for 3 days
Study: NCT02703051
Drug: Placebo Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01238783
Drug: AL-15469A 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular dosed 3 times per day for 3 days
Study: NCT01238783
Drug: AL-6515 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular dosed 3 times per day for 3 days
Study: NCT01238783
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular dosed 3 times per day for 3 days
Study: NCT01147601
Drug: Control (placebo) group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo) group
Study: NCT00002987
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002987
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002987
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02234687
Drug: Pomaglumetad Methionil 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomaglumetad Methionil 40mg, one dose, one time
Study: NCT02234687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one dose, one time
Study: NCT01493843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo corresponding to 260 mg or 340 mg pictilisib will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, placebo will be taken once daily continuously.
Study: NCT01474434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets
Study: NCT00158860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02104050
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL of Placebo Gel administered TID for 6 weeks
Study: NCT02104050
Drug: OLT1177 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL of OLT1177 Gel (5%) administered TID for 6 weeks